MedTrace Logo

DERMALIX Efficacy on Diabetic Foot Ulcers

NCT03136822 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-08-03

No results posted yet for this study

Summary

(DERMALIX) (Patent number: PCT/TR2014/000251) is a bioactive wound dressing that was developed by Ege University School of Pharmacy Department of Pharmaceutical Technology. This dressing has been categorised as Class III medical device. This clinical study will be conducted in patients with diabetic foot ulcers.

Conditions

  • Diabetic Foot
  • Diabetic Foot Ulcer

Interventions

OTHER

Standard Dressing

Standard dressing is applied for treatment of diabetic foot ulcers

DEVICE

DERMALIX

DERMALIX, a class III Medical Device will be applied in addition to standard dressing

Sponsors & Collaborators

  • Dermis Pharma

    lead INDUSTRY

Principal Investigators

  • Sevki Cetinkalp, Prof · Ege University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-26
Primary Completion
2018-05-02
Completion
2018-08-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03136822 on ClinicalTrials.gov